The PROTECT Trial for IgAN Patients
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
This study will be a randomized, active-control study that will help to determine if Sparsentan is effective at improving symptoms of IgAN.
Trial Physician / Study Coordinator
Marissa Baltazar
Email Phone (720) 420-5691Site Name
Colorado Kidney Care
1601 East 19th Avenue, Suite 4300, Denver, Colorado 80218, United States
The PROTECT Trial for IgAN Patients
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
This study will be a randomized, active-control study that will help to determine if Sparsentan is effective at improving symptoms of IgAN.
Eligibility Criteria
Patient Population
IgA Nephropathy (IgAN)
About the Drug
What is involved for the patient
Patients will take a daily dose of the study medication, and will be involved with the trial for about 2 years.
Sponsor
Retrophin, Inc.
Target Enrollment
280
Estimated End Date
April 2023
About the Trial
Study Drug
Sparsentan
Study Goal
To evaluate the potential benefit of Sparsentan on kidney function by analyzing change in proteinuria (protein in urine) and estimated glomerular filtration rate (eGFR) as compared to current standard treatment.
About the drug or intervention
Sparsentan is a tablet taken orally.